Literature DB >> 23561690

Feasibility and indicative results from a 12-month low-energy liquid diet treatment and maintenance programme for severe obesity.

Michael Lean1, Naomi Brosnahan, Philip McLoone, Louise McCombie, Anna Bell Higgs, Hazel Ross, Mhairi Mackenzie, Eleanor Grieve, Nick Finer, John Reckless, David Haslam, Billy Sloan, David Morrison.   

Abstract

BACKGROUND: There is no established primary care solution for the rapidly increasing numbers of severely obese people with body mass index (BMI) > 40 kg/m(2). AIM: This programme aimed to generate weight losses of ≥15 kg at 12 months, within routine primary care. DESIGN AND
SETTING: Feasibility study in primary care.
METHOD: Patients with a BMI ≥40 kg/m(2) commenced a micronutrient-replete 810-833 kcal/day low-energy liquid diet (LELD), delivered in primary care, for a planned 12 weeks or 20 kg weight loss (whichever was the sooner), with structured food reintroduction and then weight-loss maintenance, with optional orlistat to 12 months. RESULT: Of 91 patients (74 females) entering the programme (baseline: weight 131 kg, BMI 48 kg/m(2), age 46 years), 58/91(64%) completed the LELD stage, with a mean duration of 14.4 weeks (standard deviation [SD] = 6.0 weeks), and a mean weight loss of 16.9 kg (SD = 6.0 kg). Four patients commenced weight-loss maintenance omitting the food-reintroduction stage. Of the remaining 54, 37(68%) started and completed food reintroduction over a mean duration of 9.3 weeks (SD = 5.7 weeks), with a further mean weight loss of 2.1 kg (SD = 3.7 kg), before starting a long-term low-fat-diet weight-loss maintenance plan. A total of 44/91 (48%) received orlistat at some stage. At 12 months, weight was recorded for 68/91 (75%) patients, with a mean loss of 12.4 kg (SD = 11.4 kg). Of these, 30 (33% of all 91 patients starting the programme) had a documented maintained weight loss of ≥15 kg at 12 months, six (7%) had a 10-15 kg loss, and 11 (12%) had a 5-10 kg loss. The indicative cost of providing this entire programme for wider implementation would be £861 per patient entered, or £2611 per documented 15 kg loss achieved.
CONCLUSION: A care package within routine primary care for severe obesity, including LELD, food reintroduction, and weight-loss maintenance, was well accepted and achieved a 12-month-maintained weight loss of ≥15 kg for one-third of all patients entering the programme.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23561690      PMCID: PMC3553637          DOI: 10.3399/bjgp13X663073

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  29 in total

Review 1.  ABC of obesity. Management: part II--drugs.

Authors:  Mike Lean; Nick Finer
Journal:  BMJ       Date:  2006-10-14

2.  Evaluation of the Counterweight Programme for obesity management in primary care: a starting point for continuous improvement.

Authors: 
Journal:  Br J Gen Pract       Date:  2008-08       Impact factor: 5.386

3.  Osteoarthritis - a role for weight management in rheumatology practice: an update.

Authors:  H Bliddal; P Christensen; B F Riecke; J Aaboe; R Frederiksen; E Bartels; R Christensen
Journal:  Clin Obes       Date:  2011-02

4.  Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.

Authors:  Bjørn Richelsen; Serena Tonstad; Stephan Rössner; Søren Toubro; Leo Niskanen; Steen Madsbad; Pertti Mustajoki; Aila Rissanen
Journal:  Diabetes Care       Date:  2007-01       Impact factor: 19.112

5.  Self-reported facilitators of, and impediments to maintenance of healthy lifestyle behaviours following a supervised research-based lifestyle intervention programme in patients with type 2 diabetes.

Authors:  T P Wycherley; P Mohr; M Noakes; P M Clifton; G D Brinkworth
Journal:  Diabet Med       Date:  2012-05       Impact factor: 4.359

6.  Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine.

Authors:  M Apfelbaum; P Vague; O Ziegler; C Hanotin; F Thomas; E Leutenegger
Journal:  Am J Med       Date:  1999-02       Impact factor: 4.965

7.  Efficacy and safety of very-low-calorie diet in Taiwanese: a multicenter randomized, controlled trial.

Authors:  Wen-Yuan Lin; Chih-Hsing Wu; Nain-Feng Chu; Chih-Jen Chang
Journal:  Nutrition       Date:  2009-07-09       Impact factor: 4.008

Review 8.  Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies.

Authors:  James W Anderson; Cyril W C Kendall; David J A Jenkins
Journal:  J Am Coll Nutr       Date:  2003-10       Impact factor: 3.169

Review 9.  Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up.

Authors:  Marion J Franz; Jeffrey J VanWormer; A Lauren Crain; Jackie L Boucher; Trina Histon; William Caplan; Jill D Bowman; Nicolas P Pronk
Journal:  J Am Diet Assoc       Date:  2007-10

10.  Comparison of range of commercial or primary care led weight reduction programmes with minimal intervention control for weight loss in obesity: lighten Up randomised controlled trial.

Authors:  Kate Jolly; Amanda Lewis; Jane Beach; John Denley; Peymane Adab; Jonathan J Deeks; Amanda Daley; Paul Aveyard
Journal:  BMJ       Date:  2011-11-03
View more
  23 in total

1.  12th Roche Diabetes Care Network Meeting: April 11-13, 2019, Copenhagen, Denmark.

Authors:  Christopher G Parkin; Christine Zepezauer; Rolf Hinzmann
Journal:  Diabetes Technol Ther       Date:  2020-01-14       Impact factor: 6.118

Review 2.  Pharmacotherapy for obesity: novel agents and paradigms.

Authors:  Sean Manning; Andrea Pucci; Nicholas Finer
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

Review 3.  NICE-Accredited Commissioning Guidance for Weight Assessment and Management Clinics: a Model for a Specialist Multidisciplinary Team Approach for People with Severe Obesity.

Authors:  Richard Welbourn; John Dixon; Julian H Barth; Nicholas Finer; Carly A Hughes; Carel W le Roux; John Wass
Journal:  Obes Surg       Date:  2016-03       Impact factor: 4.129

4.  Type 2 diabetes: prevention and cure?

Authors:  Mary Pierce
Journal:  Br J Gen Pract       Date:  2013-02       Impact factor: 5.386

5.  Effects on body weight, eating behavior, and quality of life of a low-energy diet combined with behavioral group treatment of persons with class II or III obesity: A 2-year pilot study.

Authors:  Jan Karlsson; Marije Galavazi; Stefan Jansson; Johan Jendle
Journal:  Obes Sci Pract       Date:  2020-10-28

6.  Evaluation of a multidisciplinary Tier 3 weight management service for adults with morbid obesity, or obesity and comorbidities, based in primary care.

Authors:  A Jennings; C A Hughes; B Kumaravel; M O Bachmann; N Steel; M Capehorn; K Cheema
Journal:  Clin Obes       Date:  2014-07-01

7.  Formula food-reducing diets:A new evidence-based addition to the weight management tool box.

Authors:  A R Leeds
Journal:  Nutr Bull       Date:  2014-09

8.  Doctor Referral of Overweight People to a Low-Energy Treatment (DROPLET) in primary care using total diet replacement products: a protocol for a randomised controlled trial.

Authors:  Susan A Jebb; Nerys M Astbury; Sarah Tearne; Alecia Nickless; Paul Aveyard
Journal:  BMJ Open       Date:  2017-08-04       Impact factor: 2.692

9.  The Diabetes Remission Clinical Trial (DiRECT): protocol for a cluster randomised trial.

Authors:  Wilma S Leslie; Ian Ford; Naveed Sattar; Kieren G Hollingsworth; Ashley Adamson; Falko F Sniehotta; Louise McCombie; Naomi Brosnahan; Hazel Ross; John C Mathers; Carl Peters; George Thom; Alison Barnes; Sharon Kean; Yvonne McIlvenna; Angela Rodrigues; Lucia Rehackova; Sviatlana Zhyzhneuskaya; Roy Taylor; Mike E J Lean
Journal:  BMC Fam Pract       Date:  2016-02-16       Impact factor: 2.497

Review 10.  A clinical perspective of obesity, metabolic syndrome and cardiovascular disease.

Authors:  Thang S Han; Mike Ej Lean
Journal:  JRSM Cardiovasc Dis       Date:  2016-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.